Please assess the completion status of the following clinical trial:

Trial Title: Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria for the patients treated with antibiotics~* Adult patient hospitalized in a participating ward of the hospital for an expected duration of more than 24 hours.~* Treatment by ceftriaxone and / or a fluoroquinolone started by the attending physicians during hospitalization.~* No hospitalization or stay in nursing home in the previous three months.~* No use of antibiotics in the last 3 months~* Not receiving other antibiotics than ceftriaxone or FQ~* Informed consent~Inclusion criteria for the patients in the reference group~* Adult patient hospitalized in a participating ward of the hospital for an expected duration of more than 24 hours.~* Not receiving any antibiotic and not expected to receive any during hospitalization~* No hospitalization or stay in nursing home in the previous three months.~* No use of antibiotics in the last 3 months~* Informed consent~Exclusion criteria~* Pregnant or nursing women~* Patient who underwent colectomy or suffering from chronic intestinal disease (inflammatory intestinal disease or short bowel syndrome)~* Patient who used a bowel preparation solution for colonoscopy during hospitalization or in the previous week.~* Protected adult patient (deputyship or guardianship)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceftriaxone (Type: None): Patients receiving a C3G (ceftriaxone) during the hospitalization.
- Ceftriaxone + Fluoroquinolone (Type: None): ceftriaxone followed by fluoroquinolone (which is a common situation in clinical practice, Fluoroquinolone being prescribed after obtaining antibiogram).
- Fluoroquinolones (Type: None): fluoroquinolones (levofloxacin, ofloxacin, moxifloxacin or ciprofloxacin).
- Reference (Type: None): A third reference group will consist of patients hospitalized in the same services as the case patients but did not receive antibiotics (60 patients). They will have an idea of possible changes in flora during hospitalization without any antibiotics, for example due to horizontal transfer of resistant strains. This group will be composed of 60 patients who had not received antibiotics within 3 months before and not receiving for the duration of their participation.

Based on this trial design, predict the completion outcome and termination type (if applicable).